Appendix A: Search Strategy

PubMed

1. Population (plasma donor)

"plasma donor*"[TIAB] OR "plasma donat*"[TIAB]

OR (("Plasmapheresis"[Mesh:NoExp] OR "plasmapheres*"[TIAB] OR "plasmaphaeres*"[TIAB] OR "plasma collection"[TIAB] OR "plasma withdrawal"[TIAB] OR "plasma removal"[TIAB] OR "Blood component removal"[Mesh:NoExp] OR "apheres*"[TIAB] OR "aphaeres*"[TIAB] OR

"pheres*"[TIAB] OR "phaeres*"[TIAB]

OR "Plateletpheresis" [Mesh:NoExp] OR "plateletpheres*" [TIAB] OR "plateletphaeres*" [TIAB] OR thrombocytapheres* [TIAB] OR thrombocytopheres* [TIAB] OR thromboapheres* [TIAB] OR thromboapheres* [TIAB] OR thrombocytaphaeres* [TIAB] OR thrombocytophaeres* [TIAB] OR thromboaphaeres* [TIAB] OR thromboaphaeres* [TIAB] OR thromboaphaeres* [TIAB] OR thromboaphaeres* [TIAB] OR "donor*" [TIAB] OR "

2. Concept (safety)

"safety"[MESH] OR "safe*"[TIAB] OR "efficacy"[TIAB] OR "effect*"[TIAB]

OR (("adverse"[TIAB] OR "undesirable"[TIAB] OR "side"[TIAB] OR "acute"[TIAB] OR "short-term"[TIAB]

OR "long-term"[TIAB] OR "shortterm"[TIAB] OR "longterm"[TIAB] OR vital[TIAB]) AND

("reaction*"[TIAB] OR "consequence*"[TIAB] OR "event*"[TIAB] OR "outcome*"[TIAB] OR "symptom*"[TIAB]))

OR "tolerability" [TIAB] OR "harm" [TIAB] OR "complication*" [TIAB]

OR "plasmavigilance" [TIAB] OR "hemovigilance" [TIAB] OR "haemovigilance" [TIAB]

OR "donor vigilance" [TIAB]

OR "health" [TIAB] OR "monitor*" [TIAB] OR "surveillance" [TIAB]

OR "Plasmapheresis/adverse effects" [MESH] OR "Blood Component Removal/adverse effects" [Mesh]

OR "Plateletpheresis/adverse effects" [Mesh] OR "Monitoring, physiologic" [Mesh]

3. Concept (risk and prevention)

"Preventive Medicine" [Mesh] OR "prevention and control" [Subheading] OR "Health Promotion" [Mesh] OR "Risk Factors" [Mesh] OR "prevent*" [TIAB] OR "protect*" [TIAB] OR "risk factor" [TIAB] OR "Risk Assessment" [Mesh: NoExp] OR "Risk" [Mesh: NoExp] OR "donor characteristic*" [TIAB]

OR "Plasmapheresis/methods" [MESH]

Embase

1. Population (plasma donor)

'plasma donor*':ti,ab OR 'plasma donat*':ti,ab OR ((Plasmapheresis/de OR plasmapheres*:ti,ab OR plasmaphaeres*:ti,ab OR 'plasma collection':ti,ab OR 'plasma withdrawal':ti,ab OR 'plasma removal':ti,ab OR apheresis/de OR apheres*:ti,ab OR aphaeres*:ti,ab OR pheres*:ti,ab OR phaeres*:ti,ab OR thrombocytopheresis/de OR plateletpheres*:ti,ab OR plateletphaeres*:ti,ab OR thrombocytapheres*:ti,ab OR thrombocytopheres*:ti,ab OR thrombocytaphaeres*:ti,ab OR thrombocytaphaeres*:ti,ab

2. Concept (safety)

safety/exp OR safe*:ti,ab OR efficacy:ti,ab OR effect*:ti,ab
OR ((adverse:ti,ab OR undesirable:ti,ab OR side:ti,ab OR acute:ti,ab OR 'short-term':ti,ab OR 'long-term':ti,ab OR shortterm:ti,ab OR longterm:ti,ab OR vital:ti,ab) AND (reaction*:ti,ab OR consequence:ti,ab OR event*:ti,ab OR outcome*:ti,ab OR symptom*:ti,ab))
OR tolerability:ti,ab OR harm:ti,ab OR complication*:ti,ab
OR plasmavigilance:ti,ab OR hemovigilance:ti,ab OR haemovigilance:ti,ab
OR 'donor vigilance':ti,ab
OR health:ti,ab OR monitor*:ti,ab OR surveillance:ti,ab

3. Concept (risk and prevention)

OR 'physiologic monitoring'/exp

'Preventive Medicine'/exp OR 'Health Promotion'/exp OR 'Risk Factor'/exp OR prevent*:ti,ab OR protect*:ti,ab OR 'risk factor':ti,ab OR 'risk factors':ti,ab OR 'Risk Assessment'/de OR 'Risk'/de OR 'donor characteristic*:ti,ab

Cochrane Library

1. Population (plasma donor)

(plasma NEXT donor*):ti,ab,kw OR (plasma NEXT donat*):ti,ab,kw

OR (([mh ^"Plasmapheresis"] OR plasmapheres*:ti,ab,kw OR plasmaphaeres*:ti,ab,kw OR "plasma collection":ti,ab,kw OR "plasma withdrawal":ti,ab,kw OR "plasma removal":ti,ab,kw

OR [mh ^"Blood component removal"] OR apheres*:ti,ab,kw OR aphaeres*:ti,ab,kw OR pheres*:ti,ab,kw OR phaeres*:ti,ab,kw

OR [mh ^"Plateletpheresis"] OR plateletpheres*:ti,ab,kw OR plateletphaeres*:ti,ab,kw OR thrombocytap heres*:ti,ab,kw OR thrombocytopheres*:ti,ab,kw OR thromboapheres*:ti,ab,kw OR thrombophores*:ti,ab,kw OR thrombocytaphaeres*:ti,ab,kw OR thrombocytophaeres*:ti,ab,kw OR thrombophores*:ti,ab,kw OR thrombophaeres*:ti,ab,kw OR thrombophaere

AND (donor*:ti,ab,kw OR donat*:ti,ab,kw))

2. Concept (safety)

[mh "safety"] OR safe*:ti,ab,kw OR efficacy:ti,ab,kw OR effect*:ti,ab,kw OR ((adverse:ti,ab,kw OR undesirable:ti,ab,kw OR side:ti,ab,kw OR acute:ti,ab,kw OR "short-term":ti,ab,kw OR "long-term":ti,ab,kw OR shortterm:ti,ab,kw OR longterm:ti,ab,kw OR vital:ti,ab,kw) AND (reaction*:ti,ab,kw OR consequence:ti,ab,kw OR event*:ti,ab,kw OR outcome*:ti,ab,kw OR symptom*:ti,ab,kw))
OR tolerability:ti,ab,kw OR harm:ti,ab,kw OR complication*:ti,ab,kw
OR plasmavigilance:ti,ab,kw OR hemovigilance:ti,ab,kw OR haemovigilance:ti,ab,kw
OR "donor vigilance":ti,ab,kw
OR health:ti,ab,kw OR monitor*:ti,ab,kw OR surveillance:ti,ab,kw
OR [mh "Monitoring, Physiologic "]

3. Concept (risk and prevention)

[mh "Preventive Medicine"] OR [mh "Health Promotion"] OR [mh "Risk Factors"]
OR prevent*:ti,ab,kw OR protect*:ti,ab,kw OR (risk NEXT (factor OR factors)):ti,ab,kw OR [mh ^"Risk Assessment"] OR [mh ^"Risk"] OR (donor NEXT characteristic*):ti,ab,kw

Web of Science Core Collection (Science Citation Index Expanded (SCI-EXPANDED) and Conference Proceedings Citation Index- Science (CPCI-S))

1. Population (plasma donor)

TS=("plasma donor*") OR TS=("plasma donat*")

OR ((TS=("plasmapheres*") OR TS=("plasmaphaeres*") OR TS=("plasma collection") OR TS=("plasma withdrawal") OR TS=("plasma removal")

OR (TS="apheres*") OR (TS="aphaeres*") OR (TS="pheres*") OR (TS="phaeres*")

OR (TS="plateletpheres*") OR (TS="plateletphaeres*") OR (TS="thrombocytapheres*") OR (TS="thrombocytapheres*") OR (TS="thrombocytapheres*") OR (TS="thrombocytapheres*") OR (TS="thrombocytaphaeres*") OR (TS="thromboaphaeres*")) AND (TS=("donor*") OR TS=("donor*")))

2. Concept (safety)

TS=("safe*") OR TS=("efficacy") OR TS=("effect*")

OR ((TS=("adverse") OR TS=("undesirable") OR TS=("side") OR TS=("acute") OR TS=("short-term") OR TS=("long-term") OR TS=("shortterm") OR TS=("longterm") OR TS=("vital")) AND (TS=("reaction*") OR TS=("consequence*") OR

TS=("event*") OR TS=("outcome*") OR TS=("symptom*")))

OR TS=("tolerability") OR TS=("harm") OR TS=("complication*")

OR TS=("plasmavigilance") OR TS=("hemovigilance") OR TS=("haemovigilance")

OR TS=("donor vigilance")

OR TS=("health") OR TS=("monitor*") OR TS=("surveillance")

3. Concept (risk and prevention)

TS=("prevent*") OR TS=("protect*") OR TS=("risk factor") OR TS=("risk factors") OR TS=("donor characteristic*")

CINAHL (via the Ebsco interface)

1. Population (plasma donor)

(TI "plasma donor*" OR AB "plasma donor*") OR (TI "plasma donat*" OR AB "plasma donat*")

OR (((MH "Plasmapheresis") OR (TI "plasmapheres*" OR AB "plasmapheres*") OR (TI "plasmaphaeres*"

OR AB "plasmaphaeres*") OR (TI "plasma collection" OR AB "plasma collection") OR (TI "plasma withdrawal" OR AB "plasma withdrawal") OR (TI "plasma removal" OR AB "plasma removal")

OR (MH "Blood component removal") OR (TI "apheres*" OR AB "apheres*") OR (TI "aphaeres*" OR AB "aphaeres*") OR (TI "phaeres*" OR AB "phaeres*")

OR (MH "Plateletpheresis") OR (TI "plateletpheres*" OR AB "plateletpheres*") OR (TI "plateletphaeres*"

OR AB "plateletphaeres*") OR (TI "thrombocytapheres*" OR AB "thrombocytapheres*") OR (TI "thrombocytopheres*") OR (TI "thrombophores*")

OR AB "thrombapheres*") OR (TI "thromboapheres*" OR AB "thrombocytaphaeres*") OR (TI "thrombocytaphaeres*")

OR AB "thrombophores*") OR (TI "thrombocytaphaeres*") OR (TI "thrombocytaphaeres*")

OR AB "thrombophores*") OR (TI "thrombocytaphaeres*") OR (TI "thrombocytaphaeres*")

OR AB "thrombophaeres*") OR (TI "thrombocytaphaeres*") OR (TI "thrombocytaphaeres*")

OR AB "thrombophaeres*") OR (TI "thrombocytaphaeres*") OR (TI "thromboaphaeres*")

OR AB "thrombophaeres*") OR (TI "thromboaphaeres*")

OR AB "thromboaphaeres*") OR (TI "thromboaphaeres*")

OR AB "thromboaphaeres*")

OR (TI "thromboaphaeres*")

OR (TI "donor*" OR AB "donor*")

OR (TI "donor*")

OR (TI "donor*")

OR (TI "donor*")

2. Concept (safety)

(MH safety+) OR (TI safe* OR AB safe*) OR (TI effect* OR AB effect*)

OR (((TI adverse OR AB adverse) OR (TI undesirable OR AB undesirable) OR (TI side OR AB side) OR (TI acute OR AB acute) OR (TI short-term OR AB short-term) OR (TI long-term OR AB long-

term) OR (TI shortterm OR AB shortterm) OR (TI longterm OR AB longterm)

OR (TI vital OR AB vital)) AND ((TI reaction* OR AB reaction*) OR (TI consequence OR AB consequence)

OR (TI event* OR AB event*) OR (TI outcome* OR AB outcome*) OR (TI symptom* OR AB symptom*)))

OR (TI tolerability OR AB tolerability) OR (TI harm OR AB harm) OR (TI complication* OR AB complication*)

OR (TI plasmavigilance OR AB plasmavigilance) OR (TI hemovigilance OR AB hemovigilance) OR (TI hae movigilance OR AB haemovigilance)

OR (TI "donor vigilance" OR AB "donor vigilance")

OR (TI health OR AB health) OR (TI monitor* OR AB monitor*) OR (TI surveillance OR AB surveillance) OR (MH "Monitoring, physiologic"+)

3. Concept (risk and prevention)

(MH "Preventive Medicine"+)

OR "prevention and control[Subheading]" OR (MH "Risk

Factors"+) OR (TI prevent* OR AB prevent*) OR (TI protect* OR AB protect*) OR (TI "risk

factor" OR AB "risk factor") OR (TI "risk factors" OR AB "risk factors")OR (MH "Risk

Assessment") OR (TI "donor characteristic*" OR AB "donor characteristic*")

Transfusion Evidence Library

Filter: Clinical speciality > Blood Donors

((plasma OR plasmapheresis OR plasmaphaeresis OR apheresis OR aphaeresis OR phaeresis OR phaeresis OR plateletphaeresis OR thrombocytapheresis OR thrombocytopheresis OR thromboapheresis OR thromboapheresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR thrombocytophaeresis OR thromboaphaeresis OR thromboaphaeresis OR donors OR donors OR donation OR donations))

PROSPERO International Prospective Register of Systematic Reviews

((plasma OR plasmapheresis OR plasmaphaeresisOR apheresis OR aphaeresis OR phaeresis OR plateletpheresis OR plateletpheresis OR thrombocytapheresis OR thrombocytapheresis OR thrombocytapheresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR donors OR donors OR donation OR donations))

AND (safe OR safety OR effect OR ((adverse OR undesirable OR side OR acute OR "short-term" OR "long-term" OR shortterm OR longterm) AND (reaction OR event OR outcome OR symptom OR reactions OR effects OR events OR outcomes OR symptoms)) OR tolerability OR harm OR complication OR complications OR plasmavigilance OR hemovigilance OR haemovigilance OR "donor vigilance" OR health OR monitor OR monitoring OR surveillance OR prevent OR prevention OR protect OR protection OR risk OR characteristic OR characteristics)

International Clinical Trials Registry Platform (trialsearch.who.int/)

((plasma OR plasmapheresis OR plasmaphaeresis OR apheresis OR aphaeresis OR pheresis OR phaeresis OR plateletpheresis OR plateletphaeresis OR thrombocytapheresis OR thrombocytapheresis OR thromboapheresis OR thromboapheresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR thrombocytaphaeresis OR donors OR donors OR donation OR donations))

AND (safe OR safety OR effect OR ((adverse OR undesirable OR side OR acute OR "short-term" OR "long-term" OR shortterm OR longterm) AND (reaction OR event OR outcome OR symptom OR reactions OR effects OR events OR outcomes OR symptoms)) OR tolerability OR harm OR complication OR complications OR plasmavigilance OR hemovigilance OR haemovigilance OR "donor vigilance" OR health OR monitor OR monitoring OR surveillance OR prevent OR prevention OR protect OR protection OR risk OR characteristic OR characteristics)

Clinicaltrials.gov (split up into 3 searches due to character limit) search in 'Other terms' field

1) (((plasma OR plasmapheresis OR apheresis OR plateletpheresis) AND (donor OR donation)))

(safe OR safety OR effect OR ((adverse OR undesirable OR side OR acute OR "short-term" OR "long-term") AND (reaction OR event OR outcome OR symptom)))

2) (((plasma OR plasmapheresis OR apheresis OR plateletpheresis) AND (donor OR donation))) AND

(plasmavigilance OR hemovigilance OR haemovigilance OR "donor vigilance" OR monitor OR monitoring OR surveillance)

3) (((plasma OR plasmapheresis OR apheresis OR plateletpheresis) AND (donor OR donation))) AND

(tolerability OR harm OR complication OR health OR prevent OR prevention OR protect OR protection OR risk OR characteristic)

Appendix B: Data extraction form

Study informa	Study information			Population	Intervention	Comparator
Author, Year, Country	Study sponsor	Financial disclosures of the co-authors	Study design			
				Description of the used population: number of original selected individuals, gender, age, number of individuals receiving the intervention, number of individuals in control group, nationality (when different from the country listed in the first column) Inclusion and exclusion criteria of the studied population	Extensive description of the plasmapheresis: type of device; modalities (frequency, volume, duration)	Extensive description of the plasmapheresis: type of device; modalities (frequency, volume, duration)

Study findings

Outcome	Comparison (Intervention vs	Effect size	#studies, #participants	Reference
	comparator)			
Outcome (unit)				

Appendix C: Quality assessment

Study limitations

Experimental studies

Author, Year	Lack of allocation	Lack of blinding	Incomplete accounting	Selective	Other limitations
	concealment		of outcome events	outcome	
				reporting	
Ciszewski,	Lack of randomization:	unclear, but outcomes	yes	yes	Limited compliance to plasma donor
1993	yes	are less likely to be	Drop-outs are present	No detailed	regimen ("although they all promised to
	No randomization was	influenced by a lack of	but unclear whether the	information on	keep appointments, some were not able
	performed	blinding	reasons were different	differences in	to do so"): n varies between 11 and 15
			between the groups	adverse events	for weekly group, between 12 and 30
	Lack of allocation	Participants: unclear	("a few donors were	(donor	for 14-day interval group
	concealment: not	No blinding reported,	dropped from the study	acceptance) and	
	applicable	but outcomes are not	due to medical or	albumin levels	Sources of potential selection bias:
		likely to be influenced	technical reasons"; "Four	between groups	- only established donors, who
		by this lack of blinding	donors had to be		probably tolerate
			deferred because of		plasmapheresis well, were
		Personnel: unclear	protein concentrations		included (but no quantitative information is provided on
		No blinding reported,	falling below accepted		plasmapheresis history)
		but outcomes are not	limits")		- donors with protein levels
		likely to be influenced			close to the lower border of
		by this lack of blinding	Difference in proportion		accepted limits were not
			of drop-outs across		allowed to participate
		Outcome assessors:	groups		
		unclear			Donor groups "relatively closely
			Per protocol analysis		matched in gender, age and weight" at
					the start of the study, but no statistics
					to check equivalence (data not

					provided for participants included in final analysis)
Mortier, 2023,	Lack of randomization: no	Participants: yes	yes	no	Trial registered (NCT05815615) only
Belgium	Participants were	(partially)			after it was performed
	randomly assigned to	"The placebo group	Nine subjects (2 in the		
	groups via a computer-	underwent a placebo	placebo group, 4 in the		Limited compliance to plasma donor
	generated randomization	donation at the same	HF group and 3 in the		regimen (13 subjects were not
	table	frequency as LF	VHF group) gave up		compliant with the donor regimen (by
		(1x/month). All	before the end of the		missing donations), especially in the
	"The randomization	participants were	study. Withdrawal from		VHF group:
	procedure was	blinded to the group	the study was due to		-Group P: n = 17 (15 completed, all
	suboptimal since	selection.", although	personal reasons or		compliant with donor regimen)
	allocation to the high-	they were of course	impossibility to comply		-Group LF: n = 16
	frequency/very high-	aware of the frequency	with the repeated		(16 completed, 15 compliant with
	frequency group was	at which they came to	appointments.		donor regimen)
	sometimes in conflict with	the centre	Data of the drop-outs		-Group HF: n = 20 (16 completed, 14
	the availability of the		were not included in the		compliant with donor regimen)
	participant. Therefore, the	Personnel: unclear	analyses, i.e. per		-Group VHF: n = 19 (16 completed; 5
	donor was assigned to the	No blinding reported,	protocol analysis		compliant with donor regimen: 6
	first available position on	but outcomes are less			subjects missed 1 donation, 2 missed

the randomization list that	likely to be influenced		2-3 donations, 2 missed 5-6 donations,
did not conflict with his	by this lack of blinding		1 missed 10 donations))
availability. The impact of			
this suboptimal	Outcome assessors:		Sources of potential selection bias:
randomization procedure	unclear		 new and established donors
was considered to be			were eligible, but (except for 1
limited."			new donor) only established
			donors, who probably tolerate plasmapheresis well,
"At the start of the study,			pastriapheresis well, participated in the study (no
the 4 groups were not			quantitative information is
different regarding age,			provided on plasmapheresis
BMI, the amount			history)
of physical activity per			
week, VO2 peak and			35 outcomes were assessed, leading to
donation history."			an increased rate of false positives for
			which no correction was applied. Sidak
Lack of allocation			corrections were applied in contrast
concealment: unclear			analyses to compare means.
			Population limited to men aged 18-50
			(average 31.4-37.7)

Certainty of the body of evidence for the experimental studies

	Initial grading High [A]	Downgrading due to
Limitations of study design	-1	See table 'Study limitations'
Imprecision	-1	Limited sample sizes
Inconsistency	0	
Indirectness	0	Limited external validity (one old study and one study
		with men only), population of active donors

Publication bias	0	
CERTAINTY (GRADE)	Final grading Low [C]	

Observational studies

Author, Year	Inappropriate	Inappropriate	Not controlled for	Incomplete or	Other limitations
	eligibility criteria	methods for	confounding	inadequate follow-up	
		exposure and			
		outcome variables			
Grgicevic,	unclear	no	yes	yes	yes
1980					
	Selection of	No indication of	Failure of accurate	Drop-out rate was very	In addition to the different follow-
	participants limited to	differential	measurement of all known	high but similar in both	up periods, the number of
	male student	surveillance for	prognostic factors (e.g.	groups (66% in the	donations at the final outcome
	population at the	outcomes in the	body weight, BMI, age)	intervention group	assessment was also different
	University of Zagreb	interventions and		versus 67% in the	between intervention and
		comparator group.	Lack of adjustment for	comparator group).	comparison groups (155 in the
	Unclear what the		weight, baseline protein	This loss to follow-up	intervention group versus 138 in
	"national criteria for		levels in statistical analysis	could potentially	the comparator group)
	blood donors" are		(Student's t-test)	change the overall	
				results (i.e. no	Unclear whether participants were
	Unclear which total		Subgroup analysis	difference) in an	first-time or repeat plasma donors
	protein level was used		according to the number of	important way.	(i.e. no information on donation
	to exclude donors.		plasmapheresis sessions		history)
	In addition, seven		was performed (7, 15, 35,	Follow-up period was	
	donors were rejected		75, >100) for some	different between	For most biochemical outcomes no
	due to the repeated		outcomes only	intervention (2 years)	information is given on when they
	low values of total			and comparator group	were assessed (after how many
	proteins or the change			(3 years)	donations)

	in the electrophoresis of proteins, it was unclear to which group these donors were allocated.				
Grgicevic, 1983	unclear Male population, unclear whether they were students Unclear what the specific inclusion/exclusion criteria were	No indication of differential surveillance for outcomes in the interventions and comparator group.	Lack of adjustment for weight, baseline protein levels in statistical analysis (Student's t-test) Subgroup analysis according to the number of plasmapheresis sessions was performed (7, 15, 35, 75, >100)	total amount of participants at baseline: unclear Drop-out was present in both groups and there was a high variability in the number of donors at different stages of the study (problem of compliance?). This loss to follow-up could potentially change the overall results (i.e. majority of outcomes no difference) in an	Subgroup analysis: cut-offs were chosen arbitrarily and specific number of plasmapheresis sessions varied between groups Unclear whether participants were first-time or repeated plasma donors (i.e. no information on donation history)
				important way.	

				Follow-up period in	
				both groups was	
				unclear	
Rosa-Bray	no	no	no	yes	yes
2013					
	All participants were	No indication of	Variables considered to be	A total of 666 donors	Funder and lead authors (with an
	required to meet	differential	possible predictors for	were enrolled; data	active role in the trial) have an
	eligibility criteria for	surveillance for	change in cholesterol levels	from 663 donors were	(undisclosed) conflict of interest
	plasma donation	outcomes in the	included gender, age,	analysed. Two donors	
		interventions and	weight (and	who completed only	No correction for post-hoc multiple
	Potential study	comparator group.	therefore donation	one donation and one	testing
	participants were		volume), race, baseline	donor who took	
	either new		cholesterol levels,	cholesterol-lowering	Subgroups 'days between
	plasmapheresis donors		total number of donations,	medications were	donations': cut-offs were chosen
	or previous donors who		number of donations prior	excluded from analysis.	arbitrarily.
	had not donated for at		to a measurement and days		
	least 6 months.		between donations. These	Relatively few	"Participants were provided with
			variables were added and	donors (<200)	their cholesterol results 2 months
	Participants were		removed in a stepwise	completed the study.	into the study, presenting a
	between 18 and 69		procedure,	This was in part due to	possible
	years of age and met all		testing the overall effect	the inclusion of many	bias if donors began lifestyle
	routine plasma industry		and statistical significance	first-time donors in the	modifications after receiving this
	standards for weight		of each	study who did not have	information. However, donor
	(‡110 pounds), blood		predictor. The variables	first-hand familiarity	activities, including diet, medication
	pressure, pulse,		baseline cholesterol level,	with the donation	and exercise, were followed using
	temperature,		time between donations	process. Study	the visit questionnaire, and no
	haematocrit		and gender were selected	discontinuation did not	changes in these activities were
	and total protein,		as predictors in the final	appear to be due to	observed." (no information was
	passed a physical		model as the others	adverse events. Most	available in the manuscript)

showed no significant dropouts who provided examination and provided a detailed effect on cholesterol-level a reason for study Relatively few donors had high medical history. change. discontinuation gave baseline total (38 donors) or LDL reasons that were (41 donors) cholesterol Both male and female Baseline cholesterol levels unrelated to plasma were grouped according to donation or study Exact sample sizes per subgroup donors had similar the recommendations of profiles, with the typical participation. (per each donation frequency) were donor being in the the National Cholesterol not given and were estimated youngest age group, of Education Program. based on the distribution of white race and participants across baseline weighing <200 pounds. cholesterol levels, possibly resulting Caveat: Multivariable repeated measures in deviations from the true sample sizes due to differences in regression model with a general estimating distributions across baseline levels equations approach was among the different frequency used. The parameterization groups and due to rounding errors. employed in the GEE Authors were contacted twice to approach may be overly obtain the correct sample sizes, but simplistic. did not respond The current model is dependent on the choice of categories, and it is possible that modelling using other categories or nonlinear continuous variables would produce different results

	1			1	T
			Participants also completed a questionnaire to monitor changes in diet, physical activity or the use of medications that could impact cholesterol levels. However, the authors did not provide any information on this confounding factors in the results.		
Salvaggio,	unclear	no	yes	unclear	yes
1971					-
	Male prisoner population Unclear what the specific inclusion/exclusion criteria were (if present)	No indication of differential surveillance for outcomes in the interventions and comparator group.	Lack of adjustment for weight, baseline protein levels in statistical analysis No information regarding statistical analysis	No drop-out reported (in all groups), but possibly a retrospective study	No detailed/quantified information regarding the questionnaire on the frequency and severity of adverse events Not clear when outcomes were assessed precisely
	Not clear whether the study was prospective or retrospective				

Certainty of the body of evidence for the observational studies

Initial grading Low	Downgrading due to
---------------------	--------------------

CERTAINTY (GRADE)	Final grading Very low	
Plausible confounding	0	
Dose-response gradient	0	
Large magnitude of effect	0	
		Upgrading due to
Publication bias	0	
		(young age) or prisoners
		men only, most papers have populations of students
Indirectness	0	Limited external validity: old papers, most papers
Inconsistency	0	
·		·
Imprecision	-1	Limited sample sizes
Limitations of study design	-1	See table 'Study limitations'

Appendix D: Detailed synthesis of findings

Plasmapheresis twice per week versus three times per month versus once per month versus placebo

Outcome	Comparison (Intervention vs	Effect size	#studies, #participants	Reference
Outcome Albumin [g/l]	Comparison (Intervention vs comparator) Interaction between Group (placebo donation 1x/month (P); plasma donation 1x/month (LF); plasma donation 3x/month (HF); plasma donation 2x/week (VHF)) and Time (1 week before 1st donation (D0); 42 days after 1st donation (D42); 84 days after 1st donation (D84))	Group*Time Statistically significant: p <0.0001 Group differences at D84: HF vs LF: Not statistically significant: 44.7±3.2 vs 43.7±2.8 MD: 0.97, 95%CI[-0.90;2.84]a (p=0.31) HF vs P: Not statistically significant: 44.7±3.2 vs 45.9±2.7 MD: -1.16, 95%CI[-3.06;0.74]a (p=0.23) HF vs VHF: Statistically significant: 44.7±3.2 vs 40.6±2.4 MD: 4.13, 95%CI[2.26;6.00]a (p<0.0001)	#studies, #participants 1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Reference Mortier, 2023
		Statistically significant: 44.7±3.2 vs 40.6±2.4		
		Statistically significant: 43.7±2.8 vs 45.9±2.7 MD: -2.13, 95%CI[-4.03;-0.23] ^a (p=0.03) LF vs VHF: Statistically significant:		

		MD: 3.16, 95%CI[1.29;5.03] ^a (p=0.001)		
		P vs VHF:		
		Statistically significant:		
		45.9±2.7 vs 40.6±2.4		
		MD: 5.29, 95%CI[3.39;7.19] ^a (p<0.0001)		
Haemoglobin [g/dl]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Statistically significant:	(HF) vs 16 (VHF) §	
		p <0.0001		
		Constant Hilliams and DOA.		
		Group differences at D84:		
		HF vs LF:		
		Not statistically significant:		
		15.0±0.8 vs 14.5±0.8		
		MD: 0.48, 95%CI[-0.13;1.08] ^a (p=0.13)		
		LIE D		
		HF vs P:		
		Not statistically significant:		
		15.0±0.8 vs 15.1±0.77		
		MD: -0.14, 95%CI[-0.76;0.48] ^a (p=0.66)		
		HF vs VHF:		
		Statistically significant:		
		15.0±0.8 vs 13.9±0.8		
		MD: 1.1, 95%CI[0.49;1.71] ^a (p=0.001)		
		W. 1.1, 337001[0.43,1.71] (p=0.001)		
		LF vs P:		
		Not statistically significant:		
		14.5±0.8 vs 15.1±0.77		
		MD: -0.61, 95%CI[-1.23;0.00] ^a (p=0.054)		
		LF vs VHF:		
		Statistically significant:		
		14.5±0.8 vs 13.9±0.8		
		MD: 0.63, 95%CI[0.02;1.23] ^a (p=0.46)		
		P vs VHF:		
		Statistically significant:		

		15.1±0.77 vs 13.9±0.8		
		MD: 1.24, 95%CI[0.62;1.86] ^a (p=0.0001)		
Ferritin [µg/l]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Statistically significant:	(HF) vs 16 (VHF)	
		p=0.0014		
		Group differences at D84:		
		HF vs LF:		
		Statistically significant:		
		31.0±14.8 vs 74.6±66		
		MD: -43.56, 95%CI[-75.78;-11.34] ^a (p=0.01)		
		HF vs P:		
		Statistically significant:		
		31.0±14.8 vs 82.7±55.77		
		MD: -51.67, 95%CI[-84.42;-18.91] ^a (p=0.003)		
		HF vs VHF:		
		Not statistically significant:		
		31.0±14.8 vs 20.1±10		
		MD: 10.88, 95%CI[-21.35;43.10]¥ ^a (p=0.51)		
		LF vs P:		
		Not statistically significant:		
		74.6±66 vs 82.7±55.77		
		MD: -8.10, 95%CI[-40.86;24.65] ^a (p=0.63)		
		·		
		LF vs VHF:		
		Statistically significant:		
		74.6±66 vs 20.1±10		
		MD: 54.44, 95%CI[22.22;86.66] ^a (p=0.001)		
		P vs VHF:		
		Statistically significant:		
		82.7±55.77 vs 20.1±10		
		MD: 62.54, 95%CI[29.79;95.30] ^a (p=0.0003)		

C-reactive protein (CRP)	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
[mg/l]	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.9484	(HF) vs 16 (VHF) §	
Glycemia [mg/dl]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Statistically significant:	(HF) vs 16 (VHF) §	
		p=0.0361		
		Group differences at D84:		
		HF vs LF:		
		Statistically significant:		
		78.6±14.8 vs 92.4±22.4		
		MD: -13.75, 95%CI[-24.69;-2.81] ^a (p=0.02)		
		HF vs P:		
		Statistically significant:		
		78.6±14.8 vs 91.4±17.82		
		MD: -12.78, 95%CI[-23.89;-1.66] ^a (p=0.03)		
		HF vs VHF:		
		Not statistically significant:		
		78.6±14.8 vs 79.9±14.4		
		MD: -1.25, 95%CI[-12.19;9.69] ^a (p=0.82)		
		LF vs P:		
		Not statistically significant:		
		92.4±22.4 vs 91.4±17.82		
		MD: 0.98, 95%CI[-10.14;12.09] ^a (p=0.86)		
		LF vs VHF:		
		Statistically significant:		
		92.4±22.4 vs 79.9±14.4		
		MD: 12.5, 95%CI[1.56;23.44] ^a (p=0.03)		
		P vs VHF:		
		Statistically significant:		
		91.4±17.82 vs 79.9±14.4		
		MD: 11.53, 95%CI[0.41;22.64] ^a (p=0.04)		

Insulinemia [pmol/l]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Not statistically significant:	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
	The vs viii) and time (D0, D42, D04)	p=0.4047	(, 15 .6 (, 5	
Glycated hemoglobin	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
(HbA1C) [%]	HF vs VHF) and Time (D0, D42, D84)	Statistically significant:	(HF) vs 16 (VHF) §	
		p=0.0007		
		Group differences at D84:		
		HF vs LF:		
		Not statistically significant:		
		5.3±0.4 vs 5.3±0.4		
		MD: -0.06, 95%CI[-0.24;0.12] ^a (p=0.54)		
		HF vs P:		
		Not statistically significant:		
		5.3±0.4 vs 5.2±0.39		
		MD: 0.02, 95%CI[-0.16;0.21] ^a (p=0.81)		
		HF vs VHF:		
		Not statistically significant:		
		5.3±0.4 vs 5.1±0.4		
		MD: 0.15, 95%CI[-0.03;0.34] ^a (p=0.10)		
		LF vs P:		
		Not statistically significant:		
		5.3±0.4 vs 5.2±0.39		
		MD: 0.08, 95%CI[-0.10;0.26] ^a (p=0.40)		
		LF vs VHF:		
		Statistically significant:		
		5.3±0.4 vs 5.1±0.4		
		MD: 0.21, 95%CI[0.03;0.39] ^a (p=0.03)		
		P vs VHF:		
		Not statistically significant:		
		5.2±0.39 vs 5.1±0.4		
		MD: 0.13, 95%CI[-0.05;0.32] ^a (p=0.17)		

Creatine kinase (CK) [U/l]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Not statistically significant: p=0.4489	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
Total cholesterol [mg/dl]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Not statistically significant: p=0.3901	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
IgA [g/l]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Statistically significant: p<0.0001 Group differences at D84: HF vs LF: Not statistically significant: 2.10±0.64 vs 1.89±0.88 MD: 0.21, 95%CI[-0.40;0.82]³ (p=0.51) HF vs P: Not statistically significant: 2.10±0.64 vs 2.34±1.05 MD: -0.24, 95%CI[-0.86;0.38]³ (p=0.45) HF vs VHF: Not statistically significant: 2.10±0.64 vs 2.06±0.88 MD: 0.04, 95%CI[-0.57;0.65]³ (p=0.90) LF vs P: Not statistically significant: 1.89±0.88 vs 2.34±1.05 MD: -0.45, 95%CI[-1.07;0.17]³ (p=0.16) LF vs VHF: Not statistically significant: 1.89±0.88 vs 2.06±0.88 MD: -0.17, 95%CI[-0.78;0.44]³ (p=0.59)	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023

		Not statistically significant: 2.34±1.05 vs 2.06±0.88		
		MD: 0.28, 95%CI[-0.34;0.90] ^a (p=0.38)		
IgG [g/l]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
5 15/ 1	HF vs VHF) and Time (D0, D42, D84)	Statistically significant:	(HF) vs 16 (VHF) §	,
	15 1) and 1 (23, 21, 23)	p<0.0001		
	Group differences at D84:			
		HF vs LF:		
		Not statistically significant:		
		8.43±1.52 vs 8.7±2.2		
		MD: -0.27, 95%CI[-1.54;1.00] ^a (p=0.68)		
		HF vs P:		
		Statistically significant:		
		8.43±1.52 vs 10.59±1.86		
		MD: -2.16, 95%CI[-3.45;-0.87] ^a (p=0.001)		
		HF vs VHF:		
		Statistically significant:		
		8.43±1.52 vs 5.73±1.4		
		MD: 2.7, 95%CI[1.43;3.97] ^a (p<0.0001)		
		LF vs P:		
		Statistically significant:		
		8.7±2.2 vs 10.59±1.86		
		MD: -1.89, 95%CI[-3.18;-0.61] ^a (p=0.005)		
		LF vs VHF:		
		Statistically significant:		
		8.7±2.2 vs 5.73±1.4		
		MD: 2.97, 95%CI[1.70;4.24] ^a (p<0.0001)		
		P vs VHF:		
		Statistically significant:		
		10.59±1.86 vs 5.73±1.4		
		MD: 4.86, 95%CI[3.57;6.15] ^a (p<0.0001)		

IgM [g/l]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Statistically significant: p<0.0001	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
		Group differences at D84:		
		HF vs LF: Not statistically significant: 0.73±0.32 vs 0.82±0.32 MD: -0.10, 95%CI[-0.33;0.14] ^a (p=0.42)		
		HF vs P: Not statistically significant: 0.73±0.32 vs 0.89±0.43 MD: -0.17, 95%CI[-0.41;0.07] ^a (p=0.18)		
		HF vs VHF: Not statistically significant: 0.73±0.32 vs 0.66±0.24 MD: 0.07, 95%CI[-0.17;0.30] ^a (p=0.58)		
		LF vs P: Not statistically significant: 0.82±0.32 vs 0.89±0.43 MD: -0.07, 95%CI[-0.31;0.17] ^a (p=0.57)		
		LF vs VHF: Not statistically significant: 0.82±0.32 vs 0.66±0.24 MD: 0.16, 95%CI[-0.07;0.40] ^a (p=0.18)		
		P vs VHF: Not statistically significant: 0.89±0.43 vs 0.66±0.24 MD: 0.23, 95%CI[-0.01;0.47] ^a (p=0.06)		
Systolic blood pressure [mmHg]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Not statistically significant: p = 0.1499	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023

Diastolic blood pressure	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
[mmHg]	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.9039	(HF) vs 16 (VHF) §	
Body mass [kg]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.3678	(HF) vs 16 (VHF) §	
BMI [kg/m²]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.3311	(HF) vs 16 (VHF) §	
Bone mineral content	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
(BMC) [kg]	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.0803	(HF) vs 16 (VHF) §	
Fat mass [kg]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.7008	(HF) vs 16 (VHF) §	
Fat-free mass (FFM) [kg]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.7596	(HF) vs 16 (VHF) §	
FFM + BMC [kg]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.7919	(HF) vs 16 (VHF) §	
% fat	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.75	(HF) vs 16 (VHF) §	
Lactate 190W [mmol/l]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.9188	(HF) vs 16 (VHF) §	
Lactate post [mmol/l]	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.8807	(HF) vs 16 (VHF) §	
Heart rate max (HRmax)	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
[bpm]	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.9383	(HF) vs 16 (VHF) §	
Ventilation max (VEmax)	Interaction between Group (P vs LF vs	Group*Time	1, 15 (P) vs 16 (LF) vs 16	Mortier, 2023
[l/min]	HF vs VHF) and Time (D0, D42, D84)	Not statistically significant: p=0.8645	(HF) vs 16 (VHF) §	

Peak oxygen consumption (VO ₂ peak) [ml/(min*kg)]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Not statistically significant: p=0.7932	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
Oxygen pulse [ml/(beat*kg)]	Interaction between Group (P vs LF vs HF vs VHF) and Time (D0, D42, D84)	Group*Time Not statistically significant: p=0.5445	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
Haematoma [rate per 50 donations; total number of occurrences]	Group (P vs LF vs HF vs VHF)	P: 0/50; 0 occurrences LF: 0/50; 0 occurrences HF: 1.08/50; 3 occurrences (in 3 donors) VHF: 0.28/50; 2 occurrences (in 1 donor)	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
Vasovagal reactions (without loss of consciousness) [rate per 50 donations; total number of occurrences]	Group (P vs LF vs HF vs VHF)	P: 0/50; 0 LF: 0/50; 0 HF: 0.36/50; 1 occurrence VHF: 0.57/50; 4 occurrences (in 3 donors)	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
Anaemia [rate per 50 donations; total number of occurrences]	Group (P vs LF vs HF vs VHF)	P: 0/50; 0 occurrences LF: 0/50; 0 occurrences HF: 0/50; 0 occurrences VHF: 0.71/50; 5 occurrences (in 4 donors)	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023
Other adverse events ^b [rate per 50 donations; total number of occurrences]	Group (P vs LF vs HF vs VHF)	P: 0/50; 0 occurrences LF: 0/50; 0 occurrences HF: 0/50; 0 occurrences VHF: 0/50; 0 occurrences	1, 15 (P) vs 16 (LF) vs 16 (HF) vs 16 (VHF) §	Mortier, 2023

Mean ± SD, MD: mean difference, SD: standard deviation

^{*} Calculations (MD, 95%CI) done by the reviewer(s) using Review Manager software

[§] Imprecision (limited sample size)

^aMeans and standard deviations of the means were extracted from Tables 1-3 of the paper by Mortier (2023), only if the Group*Time interaction effect was significant (as evidenced by the p-values in Table S1 of the paper). MDs and standard errors of the MDs were taken from supplemental information (statistical reports) provided by the study authors via personal communication and were subsequently used to calculate the 95% CIs using Excel.

^bAdverse events were registered by Mortier (2023) in accordance with the ISBT classification tool, with the notable exception that citrate reactions were not considered since donors received preventive calcium supplements.

Weekly versus biweekly plasmapheresis

Outcome	Comparison (Intervention vs comparator)	Effect size	#studies, #participants	Reference
Total serum protein concentration [g/l] (mean±std)	Weekly vs 14-day intervals plasma donation	At 1 st month Not statistically significant: 69.4±2.9 vs 69.6±3.5 MD: -0.20, 95%CI [-2.13;1.73]	1, 15 vs 30 §	Ciszewski, 1993
		(p=0.84)* At 2 nd month Not statistically significant: 67.0±3.6 vs 67.5±3.6 MD: -0.50, 95%CI [-2.96;1.96] (p=0.69)*	1, 12 vs 26 §	
		At 3 rd month Statistically significant: 64.6±2.6 vs 67.9±3.7 MD: -3.30, 95%CI [-5.57;-1.03] (p=0.004)* in favour of biweekly plasma donation	1, 14 vs 16 §	
		At 4 th month Not statistically significant: 65.0±3.7 vs 67.7±4.6 MD: -2.70, 95%CI [-5.99;0.59] (p=0.11)*	1, 13 vs 12 §	
		At 5 th month Not statistically significant: 65.5±3.0 vs 67.2±4.9 MD: -1.70, 95%CI [-4.75;1.35] (p=0.27)*	1, 11 vs 15 §	
		At 6 th month Statistically significant: 66.2±3.0 vs 69.5±3.0 MD: -3.30, 95%CI [-5.35;-1.25] (p=0.002)* in favour of biweekly plasma donation	1, 14 vs 20 §	

Immunoglobulin G levels	Weekly vs 14-day intervals plasma	At 1st month	1, 15 vs 30 §	Ciszewski, 1993
[g/l] (mean±std)	donation	Not statistically significant:		
19, 10		8.7±1.6 vs 9.5±2.3		
		MD: -0.80, 95%CI [-1.95;0.35]		
		(p=0.17)*		
		At 2 nd month	1, 12 vs 26 §	
		Not statistically significant:		
		9.3±2.0 vs 10.4±2.0		
		MD: -1.10, 95%CI [-2.47;0.27]		
		(p=0.12)*		
		At 3 rd month	1, 14 vs 16 §	
		Not statistically significant:	'	
		8.7±1.8 vs 9.9±2.6		
		MD: -1.20, 95%CI [-2.78;0.38]		
		(p=0.14)*		
		At 4 th month	1, 13 vs 12 §	
		Not statistically significant:	1, 15 15 12 5	
		8.7±1.5 vs 9.7±1.8		
		MD: -1.00, 95%CI [-2.30;0.30]		
		(p=0.13)*		
		At 5 th month	1, 11 vs 15 §	
		Not statistically significant:	1, 11 v3 13 3	
		8.7±1.8 vs 9.7±1.9		
		MD: -1.00, 95%CI [-2.43;0.43]		
		(p=0.17)*		
		At 6 th month	1, 14 vs 20 §	
			1, 14 VS 20 9	
		Not statistically significant:		
		8.8±2.0 vs 9.8±1.9		
		MD: -1.00, 95%CI [-2.34;-0.34]		
		(p=0.14)*	4.45 20.5	C' L' 1002
Immunoglobulin A levels	Weekly vs 14-day intervals plasma	At 1st month	1, 15 vs 30 §	Ciszewski, 1993
[g/l] (mean±std)	donation	Not statistically significant:		
		1.65±0.64 vs 1.99±0.84		
		MD: -0.34, 95%CI [-0.78;0.10]		
		(p=0.13)*		
		At 2 nd month	1, 12 vs 26 §	
		Not statistically significant:		
		1.92±0.82 vs 2.21±0.86		
		MD: -0.29, 95%CI [-0.86;0.28]		

		(p=0.32)*		
		At 3 rd month	1, 14 vs 16 §	
		Not statistically significant:		
		1.84±0.8 vs 2.23±0.96		
		MD: -0.39, 95%CI [-1.02;0.24]		
		(p=0.22)*		
		At 4 th month	1, 13 vs 12 §	
		Not statistically significant:		
		1.86±0.92 vs 2.1±0.98		
		MD: -0.24, 95%CI [-0.99;0.51]		
		(p=0.53)*		
		At 5 th month	1, 11 vs 15 §	
		Not statistically significant:		
		2.1±0.86 vs 2.24±1.0		
		MD: -0.14, 95%CI [-0.86;0.58]		
		(p=0.70)*		
		At 6 th month	1, 14 vs 20 §	
		Not statistically significant:		
		1.94±0.84 vs 2.26±0.97		
		MD: -0.32, 95%CI [-0.93;0.29]		
		(p=0.31)*		
Immunoglobulin M levels	Weekly vs 14-day intervals plasma	At 1 st month	1, 15 vs 30 §	Ciszewski, 1993
[g/l] (mean±std)	donation	Not statistically significant:		
		1.69±0.82 vs 2.10±1.00		
		MD: -0.41, 95%CI [-0.96;0.14]		
		(p=0.14)*		
		At 2 nd month	1, 12 vs 26 §	
		Not statistically significant:		
		1.93±0.91 vs 2.20±1.00		
		MD: -0.27, 95%CI [-0.91;0.37]		
		(p=0.41)*		
		At 3 rd month	1, 14 vs 16 §	
		Not statistically significant:		
		1.69±0.79 vs 2.30±0.95		
		MD: -0.61, 95%CI [-1.23;0.01]		
		(p=0.05)*		
		At 4 th month	1, 13 vs 12 §	
		Not statistically significant:		
		1.65±0.70 vs 2.00±1.10		

MD: -0.35, 95%CI [-1.08;0.38]	
(p=0.35)*	
At 5 th month	1, 11 vs 15 §
Not statistically significant:	
1.77±0.93 vs 1.99±0.80	
MD: -0.22, 95%CI [-0.90;0.46]	
(p=0.53)*	
At 6 th month	1, 14 vs 20 §
Not statistically significant:	
1.73±0.84 vs 1.98±0.87	
MD: -0.25, 95%CI [-0.83;0.33]	
(p=0.40)*	

Mean ± SD, MD: mean difference, SD: standard deviation

^{*} Calculations (MD, 95%CI) done by the reviewer(s) using Review Manager software § Imprecision (limited sample size)

Three times per two weeks versus (less than) once per week

Outcome	Comparison (Intervention vs comparator)	Effect size	#studies, #participants	Reference
Total serum protein concentration [g/l] (mean±std)	3x/2 weeks vs 1x/week	Not statistically significant: 66.4±3.4 vs 66.6±3.8	1, 34 vs 33 §	Grgicevic, 1980
		MD: -0.20, 95%CI [-1.93;1.53] (p=0.82)*		
Immunoglobulin G levels [g/l] (mean±std)	3x/2 weeks vs 1x/week	Not statistically significant: 12.77±4 vs 13.41±2.83 MD: -0.64, 95%CI	1, 34 vs 33 §	Grgicevic, 1980
Immunoglobulin A levels [g/l] (mean±std)	3x/2 weeks vs 1x/week	[-2.30;1.02] (p=0.45)* Not statistically significant: 1.71±0.75 vs 1.69±0.5 MD: 0.02, 95%CI [-0.28;0.32] (p=0.90)*	1, 34 vs 33 §	Grgicevic, 1980
Immunoglobulin M levels [g/l] (mean±std)	3x/2 weeks vs 1x/week	Not statistically significant: 1.12±0.47 vs 1.18±0.6 MD: -0.06, 95%CI [-0.32;0.20] (p=0.65)*	1, 34 vs 33 §	Grgicevic, 1980
Albumins [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 39.8±2.8 vs 39.9±2.8 MD: -0.10, 95%CI [-1.44;1.24] (p=0.88)*	1, 34 vs 33 §	Grgicevic, 1980
Electrophoresis albumin [%]	3x/2 weeks vs 1x/week	Not statistically significant: 60.04±2.37 vs 60.09±2.8 MD: -0.05, 95%CI [-1.29;1.19] (p=0.94)*	1, 34 vs 33 §	Grgicevic, 1980
Globulins [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 26.6±1.9 vs 26.7±2.6 MD: -0.10, 95%CI [-1.19;0.99] (p=0.86)*	1, 34 vs 33 §	Grgicevic, 1980
Alpha 1 globulins [g/l]	3x/2 weeks vs 1x/week	After 7 donations Not statistically significant: 2.20±0.28 vs 2.18±0.28 MD: 0.02, 95%CI [-0.11;0.15] (p=0.77)*	1, 34 vs 33 §	Grgicevic, 1980

		After 15 donations Not statistically significant: 2.31±0.36 vs 2.23±0.40 MD: 0.08, 95%CI [-0.10;0.26]		
		(p=0.39)* After 35 donations Not statistically significant: 2.29±0.33 vs 2.24±0.33 MD: 0.05, 95%CI [-0.11;0.21] (p=0.54)*		
		After 75 donations Not statistically significant: 2.34±0.33 vs 2.32±0.28 MD: 0.02, 95%CI [-0.13;0.17] (p=0.79)*		
		After 155 versus 138 donations Not statistically significant: 2.25±0.3 vs 2.3±0.28 MD: -0.05, 95%CI [-0.19;0.09] (p=0.48)*		
Alpha 1 globulins [%]	3x/2 weeks vs 1x/week	Not statistically significant: 3.37±0.39 vs 3.43±0.4 MD: -0.06, 95%CI [-0.25;0.13] (p=0.53)*	1, 34 vs 33 §	Grgicevic, 1980
Alpha 2 globulins [g/l]	3x/2 weeks vs 1x/week	After 7 donations Not statistically significant: 5.39±0.67 vs 5.33±0.60 MD: 0.06, 95%CI [-0.24;0.36] (p=0.70)*	1, 34 vs 33 §	Grgicevic, 1980
		After 15 donations Not statistically significant: 5.50±0.50 vs 5.57±0.60 MD: -0.07, 95%CI [-0.33;0.19] (p=0.60)*		
		After 35 donations Not statistically significant: 5.68±0.80 vs 5.43±0.78 MD: 0.25, 95%CI [-0.13;0.63] (p=0.20)*		

		After 75 donations Not statistically significant: 5.79±0.70 vs 5.78±0.80 MD: 0.01, 95%CI [-0.35;0.37] (p=0.96)* After 155 versus 138 donations Not statistically significant: 5.70±0.64 vs 5.72±0.60 MD: -0.02, 95%CI [-0.32;0.28] (p=0.89)*		
Alpha 2 globulins [%]	3x/2 weeks vs 1x/week	Not statistically significant: 8.3±1.19 vs 8.56±0.93 MD: -0.26, 95%CI [-0.77;0.25] (p=0.32)*	1, 34 vs 33 §	Grgicevic, 1980
Beta globulins [g/l]	3x/2 weeks vs 1x/week	After 7 donations Not statistically significant: 6.38±0.51 vs 6.30±0.50 MD: 0.08, 95%CI [-0.16;0.32] (p=0.52)* After 15 donations	1, 34 vs 33 §	Grgicevic, 1980
		Not statistically significant: 6.29±0.59 vs 6.33±0.43 MD: -0.04, 95%CI [-0.29;0.21] (p=0.75)* After 35 donations		
		Not statistically significant: 6.40±0.54 vs 6.41±0.45 MD: -0.01, 95%CI [-0.25;0.23] (p=0.93)*		
		After 75 donations Not statistically significant: 6.66±0.69 vs 6.49±0.83 MD: 0.17, 95%CI [-0.20;0.54] (p=0.36)*		
		After > 100 donations (155 versus 138) Not statistically significant: 6.81±0.60 vs 6.63±0.80 MD: 0.18, 95%CI [-0.16;0.52] (p=0.30)*		

Beta globulins [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 10.12±0.86 vs 9.86±1.03 MD: 0.26, 95%CI [-0.2;0.72] (p=0.26)*	1, 34 vs 33 §	Grgicevic, 1980
Gamma globulins [%]	3x/2 weeks vs 1x/week	Not statistically significant: 18.17±1.81 vs 17.81±2.28 MD: 0.36, 95%CI [-0.63;1.35] (p=0.47)*	1, 34 vs 33 §	Grgicevic, 1980
Alpha-1-antitrypsin [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 2.01±0.38 vs 2.12±0.51 MD: -0.11, 95%CI [-0.33;0.11] (p=0.32)*	1, 34 vs 32 §	Grgicevic, 1980
Alpha-1-antitrypsin [%]	3x/2 weeks vs < 1x/week	After 1 donation (1 vs 1) Not statistically significant: 94.5±10.2 vs 94.6±10.3 λ MD: -0.10, 95%CI [-4.71;4.51] (p=0.97)*	1, 38 vs 38 §	Grgicevic, 1983
		After 7 donations (7 vs 7) Not statistically significant: 101.6±21.1 vs 108.0±22.0 λ MD: -6.40, 95%CI [-22.67;9.87] (p=0.44)*	1, 11 vs 17 §	
		After 15 donations (15 vs 15) Not statistically significant: 95.9±13.5 vs 105.5±28.0 λ MD: -9.60, 95%CI [-23.07;3.87] (p=0.16)*	1, 10 vs 27 §	
		After 35 donations (35 vs 35) Not statistically significant: 104.3±19.7 vs 100.5±22.0 λ MD: 3.80, 95%CI [-5.34;12.94] (p=0.42)*	1, 39 vs 41 §	
		After 75 donations (75 vs 75) Not statistically significant: 103.6±18.1 vs 103.4±22.3 λ MD: 0.20, 95%CI [-9.02;9.42] (p=0.97)*	1, 31 vs 43 §	
		After > 100 donations (156 vs 138) Not statistically significant:	1, 36 vs 34 §	

		93.4±12.2 vs 95.9±17.7 λ MD: -2.50, 95%CI [-9.66;4.66] (p=0.49)*		
Alpha-2-macroglobulin [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 2.27±0.59 vs 2.37±0.55 MD: -0.1, 95%CI [-0.38;0.18] (p=0.48)*	1, 34 vs 32 §	Grgicevic, 1980
Alpha-2-macroglobulin [%]	3x/2 weeks vs < 1x/week	After 1 donation (1 vs 1) Not statistically significant: 100.0±13.7 vs 100.3±13.8 λ MD: -0.30, 95%CI [-6.48;5.88] (p=0.92)*	1, 38 vs 38 §	Grgicevic, 1983
		After 7 donations (7 vs 7) Not statistically significant: 110.3±21.7 vs 105.7±19.9 λ MD: 4.6, 95%CI [-10.52;19.72] (p=0.55)*	1, 13 vs 17 §	
		After 15 donations (15 vs 15) Not statistically significant: 104.8±15.8 vs 105.2±22.1 λ MD: -0.40, 95%CI [-12.62;11.82] (p=0.95)*	1, 12 vs 27 §	
		After 35 donations (35 vs 35) Not statistically significant: 100.7±19.4 vs 100.4±17.8 λ MD: 0.30, 95%CI [-7.83;8.43] (p=0.94)*	1, 39 vs 42 §	
		After 75 donations (75 vs 75) Not statistically significant: 102.6±15.7 vs 102.5±18.3 λ MD: 0.10, 95%CI [-7.56;7.76] (p=0.98)*	1, 33 vs 43 §	
		After > 100 donations (156 vs 138) Not statistically significant: 105.4±17.2 vs 98.6±16.6 λ MD: 6.80, 95%CI [-1.12;14.72] (p=0.09)*	1, 36 vs 34 §	
Anti-thrombin III [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 0.3±0.06 vs 0.31±0.05	1, 34 vs 32 §	Grgicevic, 1980

		MD: -0.01, 95%CI [-0.04;0.02] (p=0.46)*		
Anti-thrombin III [%]	3x/2 weeks vs < 1x/week	After 1 donation (1 vs 1) Not statistically significant: 103.9±16.0 vs 104.0±15.7 λ MD: -0.10, 95%CI [-7.23;7.03] (p=0.98)*	1, 38 vs 38 §	Grgicevic, 1983
		After 7 donations (7 vs 7) Not statistically significant: 106.6±16.1 vs 96.0±15.3 λ MD: 10.60, 95%CI [-0.78;21.98] (p=0.07)*	1, 13 vs 17 §	
		After 15 donations (14 vs 16) Not statistically significant: 106.4±16.5 vs 103.8±26.1 λ MD: 2.6, 95%CI [-10.97;16.17] (p=0.71)*	1, 12 vs 27 §	
		After 35 donations (34 vs 34) Not statistically significant: 107.3±20.6 vs 102±24.1 λ MD: 5.30, 95%CI [-4.44;15.04] (p=0.29)*	1, 39 vs 42 §	
		After 75 donations (78 vs 76) Not statistically significant: 100.3±18.4 vs 100.4±16.5 λ MD: -0.10, 95%CI [-8.12;7.92] (p=0.98)*	1, 33 vs 42 §	
		After > 100 donations (156 vs 138) Not statistically significant: 102.5±17.2 vs 100.4±15.8 λ MD: 2.10, 95%CI [-5.63;9.83] (p=0.59)*	1, 36 vs 34 §	
Plasminogen [g/l]	3x/2 weeks vs 1x/week	Not statistically significant: 0.12±0.03 vs 0.12±0.04 MD: 0.0, 95%CI [-0.02;0.02] (p=1.00)*	1, 34 vs 32 §	Grgicevic, 1980
Plasminogen [%]	3x/2 weeks vs < 1x/week	After 1 session (1 vs 1): Not statistically significant: 99.02 ± 24.96 vs 98.77 ± 24.77 λ	1, 38 vs 38 §	Grgicevic, 1983

		MD: 0.25, 95%CI		
		[-10.94;11.43] (p=0.97)*		
		After 7 sessions (7 vs 7):	1, 13 vs 17 §	
		Statistically significant:		
		79.10±22.62 vs 96.56±12.60 λ		
		MD: -17.46, 95%CI		
		[-31.14;-3.78] (p=0.01)*		
		In favour of plasma donation < 1x/week		
		After 15 sessions (14 vs 16):	1, 12 vs 27 §	
		Not statistically significant:		
		92.25±22.75 vs 95.94±21.39 λ		
		MD: -3.69, 95%CI		
		[-18.88;11.50] (p=0.63)*		
		After 35 sessions (34 vs 34):	1, 39 vs 41 §	
		Not statistically significant:		
		95.08±24.10 vs 96.93±23.30 λ		
		MD: -1.84, 95%CI		
		[-12.24;8.55] (p=0.73)*		
		After 75 sessions (78 vs 76):	1, 33 vs 43 §	
		Not statistically significant:		
		92.13±20.47 vs 98.03±21.27 λ		
		MD: -5.90, 95%CI		
		[-15.35;3.54] (p=0.22)*		
		After > 100 sessions (156 vs 138):	1, 35 vs 33 §	
		Not statistically significant:		
		92.99±22.93 vs 97.30±26.25 λ		
		MD: -4.30, 95%CI		
		[-16.05;7.44] (p=0.47)*		
Fibrinogen [g/l]	3x/2 weeks vs 1x/week	Not statistically significant:	1, 21 vs 19 §	Grgicevic, 1980
		2.41±0.44 vs 2.5±0.42		
		MD: -0.09, 95%CI		
		[-0.36;0.18] (p=0.51)*		
	3x/2 weeks vs < 1x/week	After 1 session (1 vs 1):	1, 38 vs 38 §	Grgicevic, 1983
		Not statistically significant:		
		$2.64\pm0.56 \text{ vs } 2.64\pm0.50 \lambda$		
		MD: 0.0, 95%CI		
		[-0.24;0.24] (p=1.00)*		
		After 7 sessions (7 vs 7):	1, 11 vs 12 §	
		Not statistically significant:		

		2.53±0.34 vs 2.46±0.36 λ		
		MD: 0.07, 95%CI		
		[-0.21;0.36] (p=0.61)*		
		After 15 sessions (15 vs 13):	1, 28 vs 16 §	
		Not statistically significant:		
		2.74±0.60 vs 2.86±0.60 λ		
		MD: -0.12, 95%CI		
		[-0.49;0.25] (p=0.53)*		
		After 35 sessions (36 vs 36):	1, 16 vs 23 §	
		Not statistically significant:		
		2.68±0.68 vs 2.67±0.58 λ		
		MD: 0.01, 95%CI		
		[-0.40;0.42] (p=0.96)*		
		After 75 sessions (70 vs 71):	1, 25 vs 29 §	
		Not statistically significant:		
		2.57±0.45 vs 2.43±0.46 λ		
		MD: 0.14, 95%CI		
		[-0.10;0.38] (p=0.26)*		
		After > 100 sessions (175 vs 153):	1, 21 vs 19 §	
		Not statistically significant:		
		2.41±0.43 vs 2.50±0.41 λ		
		MD: -0.08, 95%CI		
		[-0.34;0.18] (p=0.53)*		
Factor V [u/l x 10 ³]	3x/2 weeks vs < 1x/week	After 1 session (1 vs 1):	1, 38 vs 38 §	Grgicevic, 1983
		Not statistically significant:		
		0.86±0.10 vs 0.86±0.10 λ		
		MD: 0.00, 95%CI		
		[-0.05;0.05] (p=0.95)*		
		After 7 sessions (7 vs 7):	1, 11 vs 12 §	
		Statistically significant:		
		0.87±0.07 vs 0.93±0.07 λ		
		MD: -0.06, 95%CI		
		[-0.12;-0.00] (p=0.04)*		
		In favour of plasma donation < 1x/week		
		After 15 sessions (15 vs 13):	1, 22 vs 16 §	
		Statistically significant:		
		0.80±0.01 vs 0.88±0.11 λ		
		MD: -0.07, 95%CI		
		[-0.14;-0.01] (p=0.03)*		

		In favour of plasma donation < 1x/week		
		After 35 sessions (36 vs 36):	1, 16 vs 23 §	
		Not statistically significant:		
		0.84±0.08 vs 0.89±0.10		
		MD: -0.05, 95%CI		
		[-0.11;0.01] (p=0.10)*		
		After 75 sessions (70 vs 71):	1, 24 vs 29 §	
		Statistically significant:		
		0.91±0.11 vs 0.84±0.11 λ		
		MD: 0.07, 95%CI		
		[0.01;0.13] (p=0.03)*		
		In favour of plasma donation < 3x/2 weeks		
		After >100 sessions (175 vs 153):	1, 21 vs 19 §	
		Not statistically significant:	,	
		0.89±0.13 vs 0.82±0.14 λ		
		MD: 0.07, 95%CI		
		[-0.01;0.16] (p=0.08)*		
Factor VIII [u/l x 10 ³]	3x/2 weeks vs < 1x/week	After 1 session (1 vs 1):	1, 37 vs 37 §	Grgicevic, 1983
		Not statistically significant:		
		0.98±0.22 vs 0.97±0.22 λ		
		MD: 0.00, 95%CI		
		[-0.10;0.10] (p=0.96)*		
		After 7 sessions (7 vs 7):	1, 11 vs 12 §	
		Not statistically significant:		
		0.91±0.18 vs 0.96±0.18 λ		
		MD: -0.05, 95%CI		
		[-0.20;0.10] (p=0.52)*		
		After 15 sessions (15 vs 13):	1, 22 vs 16 §	
		Not statistically significant:		
		0.98±0.18 vs 0.93±0.15 λ		
		MD: 0.05, 95%CI		
		[-0.05;0.16] (p=0.35)*		
		After 35 sessions (36 vs 36):	1, 16 vs 22 §	
		Not statistically significant:		
		1.05±0.21 vs 0.97±0.15 λ		
		MD: 0.08, 95%CI		
		[-0.04;0.21] (p=0.19)*		
		After 75 sessions (70 vs 71):	1, 24 vs 28 §	
		Not statistically significant:		

		0.95±0.13 vs 1.03±0.22 λ MD: -0.08, 95%CI [-0.17;0.02] (p=0.13)*		
		After > 100 sessions (175 vs 153): Not statistically significant: 0.95 ± 0.16 vs 0.97 ± 0.15 λ MD: -0.02 , 95% CI [-0.12;0.07] (p=0.63)*	1, 21 vs 19 §	
Alkaline phosphatase [u/l]	3x/2 weeks vs 1x/week	Not statistically significant: 92.17±19.47 vs 85.4±15.99 MD: 6.77, 95%CI [-3.29;16.83] (p=0.19)*	1, 28 vs 20 §	Grgicevic, 1980
GOT [u/l]	3x/2 weeks vs 1x/week	Not statistically significant: 14.5±4.15 vs 14.68±6.79 MD: -0.18, 95%CI [-3.54;3.18] (p=0.92)*	1, 34 vs 19 §	Grgicevic, 1980
GPT [u/l]	3x/2 weeks vs 1x/week	Not statistically significant: 14.94±6.92 vs 15.06±7.76 MD: -0.12, 95%CI [-4.39;4.15] (p=0.96)*	1, 34 vs 18 §	Grgicevic, 1980

Mean ± SD, MD: mean difference, SD: standard deviation

^{*} Calculations (MD, 95%CI) done by the reviewer(s) using Review Manager software

[§] Imprecision (limited sample size)

 $[\]lambda$ data extracted from graph using WebPlotDigitizer

Twice per week versus no plasmapheresis for more than two years, for one to two years, or for one year or less

Outcome	Comparison (Intervention vs comparator)	Effect size	#studies, #participants	Reference
IgG [g/l ^a]	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 7.32±1.87 vs 7.67±1.55 MD: -0.35, 95%CI [-1.33;0.63] (p=0.48)*	1, 24 vs 23 §	Salvaggio, 1971
	2x/week for >2 years vs ≤1 year	Not statistically significant: 8.60±1.83 vs 7.67±1.55 MD: 0.93, 95%CI [-0.05;1.91] (p=0.06)*	1, 23 vs 23 §	
	2x/week for >2 years vs 1-2 years	Statistically significant: 8.60±1.83 vs 7.32±1.87 MD: 1.28, 95%CI [0.22;2.34] (p=0.02)* In favour of 1-2 years	1, 23 vs 24 §	
	2x/week for >2 years vs no plasmapheresis	Statistically significant: 8.60±1.83 vs 11.80±2.92 MD: -3.20, 95%CI [-4.53;-1.87] (p<0.00001)* In favour of no plasmapheresis	1, 23 vs 27 §	
	2x/week for 1-2 years vs no plasmapheresis	Statistically significant: 7.32±1.87 vs 11.80±2.92 MD: -4.48, 95%CI [-5.81;-3.15] (p<0.00001)* In favour of no plasmapheresis	1, 24 vs 27 §	
	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 7.67±1.55 vs 11.80±2.92 MD: -4.13, 95%CI [-5.40;-2.86] (p<0.00001)* In favour of no plasmapheresis	1, 23 vs 27 §	
Low IgG levels (i.e. level below lower limits of normal range for both groups without	2x/week for >2 years vs 1-2 years	Not statistically significant: 11/23 vs 16/24 § RR: 0.72, 95%CI [0.43;1.20] ¥ (p=0.20)	1, 23 vs 24	Salvaggio, 1971

plasmapheresis (normal Louisiane prisoners) and Behring values (healthy European civilians)				
<u> </u>	2x/week for >2 years vs ≤1 year	Not statistically significant: 11/23 vs 15/23 § RR: 0.73, 95%CI [0.44;1.23] ¥ (p=0.24)	1, 23 vs 23	
	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 16/24 vs 15/23 § RR: 1.02, 95%CI [0.68;1.54] ¥ (p=0.92)	1, 24 vs 23	
	2x/week for >2 years vs no plasmapheresis	Statistically significant: 11/23 vs 2/25 § RR: 5.98, 95%CI [1.48;24.15] (p=0.01) In favour of no plasmapheresis	1, 23 vs 25	
	2x/week for 1-2 years vs no plasmapheresis	Statistically significant: 16/24 vs 2/25 § RR: 8.33, 95%CI [2.14;32.44] (p=0.002) In favour of no plasmapheresis	1, 24 vs 25	
	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 15/23 vs 2/25 § RR: 8.15, 95%CI [2.09;31.84] (p=0.003) In favour of no plasmapheresis	1, 23 vs 25	
IgA [g/l ^a]	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 1.20±0.32 vs 1.28±0.43 MD: -0.08, 95%CI [-0.30;0.14] (p=0.47)*	1, 24 vs 23 §	Salvaggio, 1971
	2x/week for >2 years vs ≤1 year	Not statistically significant: 1.32±0.27 vs 1.28±0.43 MD: 0.04, 95%CI [-0.17;0.25] (p=0.71)*	1, 23 vs 23 §	
	2x/week for >2 years vs 1-2 years	Not statistically significant: 1.32±0.27vs 1.20±0.32 MD: 0.12, 95%CI [-0.05;0.29] (p=0.16)*	1, 23 vs 24 §	

	2x/week for >2 years vs no plasmapheresis	Statistically significant: 1.32±0.27 vs 1.78±0.89 MD: -0.46, 95%CI [-0.81;-0.11] (p=0.01)* In favour of no plasmapheresis	1, 23 vs 27 §	
	2x/week for 1-2 years vs no plasmapheresis	Statistically significant: 1.20±0.32 vs 1.78±0.89 MD: -0.58, 95%CI [-0.94;-0.22] (p=0.002)* In favour of no plasmapheresis	1, 24 vs 27 §	
	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 1.28±0.43 vs 1.78±0.89 MD: -0.50, 95%CI [-0.88;-0.12] (p=0.010)* In favour of no plasmapheresis	1, 23 vs 27 §	
Low IgA levels (i.e. level below lower limits of normal range for both groups without plasmapheresis (normal Louisiane prisoners) and Behring values (healthy European civilians)	2x/week for >2 years vs 1-2 years	Not statistically significant: 10/23 vs 14/24 § RR: 0.75, 95%CI [0.42;1.33] ¥ (p=0.32)	1, 23 vs 24	Salvaggio, 1971
	2x/week for >2 years vs ≤1 year	Not statistically significant: 10/23 vs 13/23 § RR: 0.77, 95%CI [0.43;1.38] ¥ (p=0.38)	1, 23 vs 23	
	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 14/24 vs 13/23 § RR: 1.03, 95%CI [0.63;1.69] ¥ (p=0.90)	1, 24 vs 23	
	2x/week for >2 years vs no plasmapheresis	Not statistically significant: 10/23 vs 5/25 § RR: 2.17, 95%CI [0.87;5.41] ¥ (p=0.10)	1, 23 vs 25	
	2x/week for 1-2 years vs no plasmapheresis	Statistically significant: 14/24 vs 5/25 § RR: 2.92, 95%CI [1.24;6.85] (p=0.01)	1, 24 vs 25	

		In favour of no plasmapheresis		
	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 13/23 vs 5/25 §	1, 23 vs 25	
		RR: 2.83, 95%CI [1.19;6.69] (p=0.02) In favour of no plasmapheresis		
IgM [g/l³]	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 0.88±0.46 vs 0.71±0.18 MD: 0.17, 95%CI [-0.03;0.37] (p=0.09)*	1, 24 vs 23 §	Salvaggio, 1971
	2x/week for >2 years vs ≤1 year	Not statistically significant: 0.75±0.33 vs 0.71±0.18 MD: 0.04, 95%CI [-0.11;0.19] (p=0.61)*	1, 23 vs 23 §	
	2x/week for >2 years vs 1-2 years	Not statistically significant: 0.75±0.33 vs 0.88±0.46 MD: -0.13, 95%CI [-0.36;0.10] (p=0.26)*	1, 23 vs 24 §	
	2x/week for >2 years vs no plasmapheresis	Statistically significant: 0.75±0.33 vs 1.20±0.59 MD: -0.45, 95%CI [-0.71;-0.19] (p=0.0007)* In favour of no plasmapheresis	1, 23 vs 27 §	
	2x/week for 1-2 years vs no plasmapheresis	Statistically significant: 0.88±46 vs 1.20±0.59 MD: -0.32, 95%CI [-0.61;-0.03] (p=0.03)* In favour of no plasmapheresis	1, 24 vs 27 §	
	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 0.71±0.18 vs 1.20±0.59 MD: -0.49, 95%CI [-0.72;-0.26] (p<0.0001)* In favour of no plasmapheresis	1, 23 vs 27 §	
Low IgM levels (i.e. level below lower limits of normal range for both groups without plasmapheresis (normal Louisiane	2x/week for >2 years vs 1-2 years	Not statistically significant: 17/23 vs 14/24 § RR: 1.27, 95%CI [0.84;1.92] ¥ (p=0.27)	1, 23 vs 24	Salvaggio, 1971

prisoners) and Behring values				
(healthy European civilians)				
	2x/week for >2 years vs ≤1 year	Not statistically significant: 17/23 vs 17/23 § RR: 1.00, 95%CI [0.71;1.41] ¥ (p=1.00)	1, 23 vs 23	
	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 14/24 vs 17/23 § RR: 0.49, 95%CI [0.14;1.70] ¥ (p=0.26)	1, 24 vs 23	
	2x/week for >2 years vs no plasmapheresis	Statistically significant: 17/23 vs 6/25 § RR: 3.08, 95%CI [1.47;6.45] (p=0.003) In favour of no plasmapheresis	1, 23 vs 25	
	2x/week for 1-2 years vs no plasmapheresis	Statistically significant: 14/24 vs 6/25 § RR: 2.43, 95%CI [1.12;5.28] (p=0.02) In favour of no plasmapheresis	1, 24 vs 25	
	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 17/23 vs 6/25 § RR: 3.08, 95%CI [1.47;6.45] (p=0.003) In favour of no plasmapheresis	1, 23 vs 25	
Albumin [g/l ^a]	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 25.74±3.80 vs 27.73±3.23 MD: -1.99, 95%CI [-4.00;0.02] (p=0.05)*	1, 24 vs 23 §	Salvaggio, 1971
	2x/week for >2 years vs ≤1 year	Not statistically significant: 26.17±2.32 vs 27.73±3.23 MD: -1.56, 95%CI [-3.19;0.07] (p=0.06)*	1, 23 vs 23 §	
	2x/week for >2 years vs 1-2 years	Not statistically significant: 26.17±2.32 vs 25.74±3.80 MD: 0.43, 95%CI [-1.36;2.22] (p=0.64)*	1, 23 vs 24 §	

	2x/week for >2 years vs no	Statistically significant:	1, 23 vs 27 §	
	plasmapheresis	26.17±2.32 vs 31.99±4.57	,	
	plasmapheresis	MD: -5.82, 95%CI		
		[-7.79;-3.85] (p<0.00001)*		
		In favour of no plasmapheresis		
	2x/week for 1-2 years vs no	Statistically significant:	1, 24 vs 27 §	
	plasmapheresis	25.74±3.80 vs 31.99±4.57		
	P	MD: -6.25, 95%CI		
		[-8.55;-3.95] (p<0.00001)*		
		In favour of no plasmapheresis		
	2x/week for ≤1 year vs no	Statistically significant:	1, 23 vs 27 §	
	plasmapheresis	27.73±3.23 vs 31.99±4.57		
	' '	MD: -4.26, 95%CI		
		[-6.43;-2.09] (p=0.0001)*		
		In favour of no plasmapheresis		
B1-globulin [mg%²]	2x/week for 1-2 years vs ≤1 year	Not statistically significant:	1, 24 vs 23 §	Salvaggio, 1971
		0.64±0.13 vs 0.70±0.14		
		MD: -0.06, 95%CI		
		[-0.14;0.02] (p=0.13)*		
	2x/week for >2 years vs ≤1 year	Not statistically significant:	1, 23 vs 23 §	
		0.65±0.16 vs 0.70±0.14		
		MD: -0.05, 95%CI		
		[-0.14;0.03] (p=0.26)*		
	2x/week for >2 years vs 1-2 years	Not statistically significant:	1, 23 vs 24 §	
		0.65±0.16 vs 0.64±0.13		
		MD: 0.01, 95%CI		
		[-0.07;0.09] (p=0.81)*		
	2x/week for >2 years vs no	Statistically significant:	1, 23 vs 27 §	
	plasmapheresis	0.65±0.16 vs 0.83±0.16		
		MD: -0.18, 95%CI		
		[-0.27;-0.09] (p<0.0001)*		
		In favour of no plasmapheresis		
	2x/week for 1-2 years vs no	Statistically significant:	1, 24 vs 27 §	
	plasmapheresis	0.64±0.13 vs 0.83±0.16		
		MD: -0.19, 95%CI		
		[-0.27;-0.11] (p<0.00001)*		
		In favour of no plasmapheresis		

	2x/week for ≤1 year vs no plasmapheresis	Statistically significant: 0.70±0.14 vs 0.83±0.16	1, 23 vs 27 §	
	plasmapheresis	MD: -0.13, 95%CI		
		[-0.21;-0.05] (p=0.002)*		
		In favour of no plasmapheresis		
Transferrin [mg/dl]	2x/week for 1-2 years vs ≤1 year	Not statistically significant:	1, 24 vs 23 §	Salvaggio, 1971
-		178±23 vs 170±21		
		MD: 8, 95%CI		
		[-4.58;20.58] (p=0.21)*		
	2x/week for >2 years vs ≤1 year	Not statistically significant:	1, 23 vs 23 §	
		173±38 vs 170±21		
		MD: 3, 95%CI		
		[-14.74;20.74] (p=0.74)*		
	2x/week for >2 years vs 1-2 years	Not statistically significant:	1, 23 vs 24 §	
		173±38 vs 178±23		
		MD: -5, 95%CI		
		[-23.05;13.05] (p=0.59)*		
	2x/week for >2 years vs no	Not statistically significant:	1, 23 vs 27 §	
	plasmapheresis	173±38 vs 193±46		
		MD: -20, 95%CI		
		[-43.29;-3.29] (p=0.09)*		
	2x/week for 1-2 years vs no	Not statistically significant:	1, 24 vs 27 §	
	plasmapheresis	178±23 vs 193±46		
		MD: -15, 95%CI		
		[-34.64;4.64] (p=0.13)*		
	2x/week for ≤1 year vs no	Statistically significant:	1, 23 vs 27 §	
	plasmapheresis	170±21 vs 193±46		
	, ,	MD: -23, 95%CI		
		[-42.36;-3.64] (p=0.02)*		
		In favour of no plasmapheresis		
Ceruloplasmin [mg/dl]	2x/week for 1-2 years vs ≤1 year	Not statistically significant:	1, 24 vs 23 §	Salvaggio, 1971
		34±12 vs 31±8		
		MD: 3, 95%CI		
		[-2.81;8.81] (p=0.31)*		
	2x/week for >2 years vs ≤1 year	Not statistically significant:	1, 23 vs 23 §	
		31±13 vs 31±8		
		MD: 0, 95%CI		
		[-6.24;6.24] (p=1)*		

	2x/week for >2 years vs 1-2 years	Not statistically significant: 31±13 vs 34±12 MD: -3, 95%CI [-10.16;4.16] (p=0.41)*	1, 23 vs 24 §	
	2x/week for >2 years vs no plasmapheresis	Not statistically significant: 31±13 vs 31±11 MD: 0, 95%CI [-6.74;6.74] (p=1.00)*	1, 23 vs 27 §	
	2x/week for 1-2 years vs no plasmapheresis	Not statistically significant: 34±12 vs 31±11 MD: 3, 95%CI [-3.35;9.35] (p=0.35)*	1, 24 vs 27 §	
	2x/week for ≤1 year vs no plasmapheresis	Not statistically significant: 31±8 vs 31±11 MD: 0, 95%CI [-5.28;5.28] (p=1.00)*	1, 23 vs 27 §	
Haptoglobin [mg/dl]	2x/week for 1-2 years vs ≤1 year	Not statistically significant: 154±65 vs 145±48 MD: 9, 95%CI [-23.57;41.57] (p=0.59)*	1, 24 vs 23 §	Salvaggio, 1971
	2x/week for >2 years vs ≤1 year	Not statistically significant: 137±41 vs 145±48 MD: -8, 95%CI [-33.8;17.8] (p=0.54)*	1, 23 vs 23 §	
	2x/week for >2 years vs 1-2 years	Not statistically significant: 137±41 vs 154±65 MD: -17, 95%CI [-47.94;13.94] (p=0.28)*	1, 23 vs 24 §	
	2x/week for >2 years vs no plasmapheresis	Not statistically significant: 137±41 vs 129±52 MD: 8, 95%CI [-17.80;33.80] (p=0.54)*	1, 23 vs 27 §	
	2x/week for 1-2 years vs no plasmapheresis	Not statistically significant: 154±65vs 129±52 MD: 25, 95%CI [-7.57;57.57] (p=0.13)*	1, 24 vs 27 §	
	2x/week for ≤1 year vs no plasmapheresis	Not statistically significant: 145±48 vs 129±52 MD: 16, 95%CI	1, 23 vs 27 §	

	I [-11 7 <i>1</i> · <i>1</i> 3 7 <i>1</i>] (n−0 26)*	
	[1 1.7 1, 15.7 1] (P 0.20)	

Mean ± SD, MD: mean difference, SD: standard deviation

^{*} Calculations (MD, 95%CI) done by the reviewer(s) using Review Manager software

[§] Imprecision (limited sample size or low number of events)

almmunoglobulin and B1-globulin concentrations were expressed in mg% in the paper by Salvaggio et al. (1971). To facilitate comparison between study data, we converted mg% to g/l.

Plasma donation interval 2-4 days versus 5-9 days versus ≥10 days

Outcome	Comparison (Intervention vs comparator)	Effect size	#studies, #participants	Reference
Predicted change in total cholesterol	2-4 days vs 5-9 days in between donations (during 16 weeks)	Males: High at baseline (≥240): Statistically significant: -32.1±4 vs -13.8±3.9 λ MD: -18.3, 95%CI	1, 9 vs 6 §	Rosa-Bray, 2013
		[-22.37;-14.23] (p<0.00001)* In favour of 2-4 days in between donations		
		Males: Higher than desired at baseline (200-239): Statistically significant: -23.5±2.1 vs -9±2 λ MD: -14.5, 95%CI [-15.7;-13.3] (p<0.00001)* In favour of 2-4 days in between donations	1, 27 vs 19 §	
		Males: Acceptable at baseline (<200): More Statistically significant: $-5\pm1.1 \text{ vs } 6.9\pm1.5 \lambda$ MD: -11.9, 95%CI [-12.29;-11.51] (p<0.00001)* In favour of 2-4 days in between donations	1, 110 vs 77 §	
		Females: High at baseline (≥240): Statistically significant: -46.6±5.2 vs -32±5 λ MD: -14.6, 95%CI [-22.26;-6.94] (p=0.0002)* In favour of 2-4 days in between donations	1, 3 vs 4 §	
		Females: Higher than desired at baseline (200-239): Statistically significant: -22±2.8 vs -10.7±2.7 λ MD: -11.3, 95%CI	1, 12 vs 15 §	

	[-13.39;-9.21] (p<0.00001)*	
	In favour of 2-4 days in between donations	
	Females:	1, 39 vs 48 §
	Acceptable at baseline (<200):	
	Statistically significant:	
	-7.3±1.6 vs 1.6±1.4 λ	
	MD: -8.9, 95%CI	
	[-9.54;-8.26] (p<0.00001)*	
	In favour of 2-4 days in between donations	
2-4 days vs ≥ 10 days in between	Males:	1, 9 vs 9 §
donations (during 16 weeks)	High at baseline (≥240):	
definations (during to weeks)	Statistically significant:	
	-32.1±4 vs -17±3.8 λ	
	MD: -15.1, 95%CI	
	[-18.7;-11.5] (p<0.00001)*	
	In favour of 2-4 days in between donations	
	Males:	1, 27 vs 29 §
	Higher than desired at baseline (200-239):	
	Statistically significant:	
	-23.5±2.1 vs -2.8±2.2 λ	
	MD: -20.7, 95%CI	
	[-21.83;-19.57] (p<0.00001)*	
	In favour of 2-4 days in between donations	
	Males:	1, 110 vs 121 §
	Acceptable at baseline (<200):	
	Statistically significant:	
	-5±1.1 vs 7.8±1 λ	
	MD: -12.8, 95%CI	
	[-13.07;-12.53] (p<0.00001)*	
	In favour of 2-4 days in between donations	
	Females:	1, 3 vs 7 §
	High at baseline (≥240):	
	Statistically significant:	
	-46.6±5.2 vs -20.8±5.1 λ	
	MD: -25.8, 95%CI	
	[-32.79;-18.81] (p<0.00001)*	
	In favour of 2-4 days in between donations	
	Females:	1, 12 vs 30 §
	Higher than desired at baseline (200-239):	

	T	
	Statistically significant:	
	-22±2.8 vs -7.3±2.6 λ	
	MD: -14.7, 95%CI	
	[-16.54;-12.86] (p<0.00001)*	
	In favour of 2-4 days in between donations	
	Females:	1, 39 vs 98 §
	Acceptable at baseline (<200):	
	Statistically significant:	
	-7.3±1.6 vs 3.3±1.7 λ	
	MD: -10.6, 95%CI	
	[-11.2;-10] (p<0.00001)*	
	In favour of 2-4 days in between donations	
5-9 days vs ≥ 10 days in between	Males:	1, 6 vs 9 §
1	High at baseline (≥240):	., 0 . 3 3 3
donations (during 16 weeks)	Not statistically significant:	
	-13.8±3.9 vs -17±3.8 λ	
	MD: 3.2, 95%CI	
	[-0.79;7.19] (p=0.12)*	
		1, 19 vs 29 §
	Males:	1, 19 VS 29 9
	Higher than desired at baseline (200-239):	
	Statistically significant:	
	-9±2 vs -2.8±2.2 λ	
	MD: -6.2, 95%CI	
	[-7.4;-5] (p<0.00001)*	
	In favour of 5-9 days in between donations	
	Males:	1, 77 vs 121 §
	Acceptable at baseline (<200):	
	Statistically significant:	
	6.9±1.5 vs 7.8±1 λ	
	MD: -0.9, 95%CI	
	[-1.28;-0.52] (p<0.00001)*	
	In favour of 5-9 days in between donations	
	Females:	1, 5 vs 7 §
	High at baseline (≥240):	
	Statistically significant:	
	-32±5 vs -20.8±5.1 λ	
	MD: -11.2, 95%CI	
	[-17.39;-5.01] (p=0.0004)*	
	In favour of 2-4 days in between donations	
	in juvour of 2-4 days in between donations	

		Females:	1, 15 vs 30 §	
			1, 15 VS 50 9	
		Higher than desired at baseline (200-239):		
		Statistically significant:		
		-10.7±2.7 vs -7.3±2.6 λ		
		MD: -3.4, 95%CI		
		[-5.05;-1.75] (p<0.0001)*		
		In favour of 2-4 days in between donations		
		Females:	1, 48 vs 98 §	
		Acceptable at baseline (<200):		
		Statistically significant:		
		1.6±1.4 vs 3.3±1.7 λ		
		MD: -1.7, 95%CI		
		[-2.22;-1.18] (p<0.00001)*		
		In favour of 2-4 days in between donations		
Predicted change in LDL cholesterol	2-4 days vs 5-9 days in between	Males:	1, 9 vs 6 §	Rosa-Bray, 2013
l redicted change in LDL cholesteror		High at baseline (≥160):	1, 5 v3 0 3	103a-bray, 2013
	donations (during 16 weeks)	Statistically significant:		
		-34.6±3.8 vs -17.8±4 λ		
		MD: -16.8, 95%CI		
		[-20.85;-12.75] (p<0.00001)*		
		In favour of 2-4 days in between donations		
		Males:	1, 24 vs 17 §	
		Higher than desired at baseline (130-159):		
		Statistically significant:		
		-15.3±1.9 vs -4.6±1.9 λ		
		MD: -10.7, 95%CI		
		[-11.88;-9.52] (p<0.00001)*		
		In favour of 2-4 days in between donations		
		Males:	1, 112 vs 79 §	
		Acceptable at baseline (<130):	1, 112 V3 1 J 3	
		Statistically significant:		
		-2.2±1 vs 5.4±1 λ		
		MD: -7.6, 95%CI		
		[-7.89;-7.31] (p<0.00001)*		
		In favour of 2-4 days in between donations		
		Females:	1, 3 vs 4 §	
		High at baseline (≥160):		
		Statistically significant:		
		-35.3±5 vs -20.8±4.8 λ		

		MD: -14.5, 95%CI	
		[-21.86;-7.14] (p=0.0001)*	
		In favour of 2-4 days in between donations	
		Females:	1, 9 vs 11 §
		Higher than desired at baseline (130-159):	
		Statistically significant:	
		-18.4±2.8 vs -10.5±2.5 λ	
		MD: -7.9, 95%CI	
		[-10.25;-5.55] (p<0.00001)*	
		In favour of 2-4 days in between donations	
		Females:	1, 41 vs 51 §
		Acceptable at baseline (<130):	
		Statistically significant:	
		-1.9±0.6 vs 3.7±0.9 λ	
		MD: -5.6, 95%CI	
		[-5.91;-5.29] (p<0.00001)*	
		In favour of 2-4 days in between donations	
2-4	4 days vs ≥ 10 days in between	Males:	1, 9 vs 10 §
do	onations (during 16 weeks)	High at baseline (≥160):	
	, 3	Statistically significant:	
		-34.6±3.8 vs -19.1±4 λ	
		MD: -15.5, 95%CI	
		[-19.01;-11.99] (p<0.00001)*	
		In favour of 2-4 days in between donations	
		Males:	1, 24 vs 27 §
		Higher than desired at baseline (130-159):	
		Statistically significant:	
		-15.3±1.9 vs -0.4±1.8 λ	
		MD: -14.9, 95%CI	
		[-15.92;-13.88] (p<0.00001)*	
		In favour of 2-4 days in between donations	
		Males:	1, 112 vs 124 §
		Acceptable at baseline (<130):	
		Statistically significant:	
		-2.2±1 vs 6.8±1.2 λ	
		MD: -9, 95%CI	
		[-9.28;-8.72] (p<0.00001)*	
		In favour of 2-4 days in between donations	

	Famalan	1.50.5
	Females:	1, 5 vs 8 §
	High at baseline (≥160):	
	Statistically significant:	
	-35.3±5 vs -25.6±5 λ	
	MD: -9.7, 95%CI	
	[-16.33;-3.07] (p=0.004)*a	
	In favour of 2-4 days in between donations	
	Females:	1, 9 vs 23 §
	Higher than desired at baseline (130-159)	:
	Statistically significant:	
	-18.4±2.8 vs -7.3±2.6 λ	
	MD: -11.1, 95%CI	
	[-13.22;-8.98] (p<0.00001)*	
	In favour of 2-4 days in between donations	s
	Females:	1, 41 vs 104 §
	Acceptable at baseline (<130):	
	Statistically significant:	
	-1.9±0.6 vs 3±0.8 λ	
	MD: -4.9, 95%CI	
	[-5.14;-4.66] (p<0.00001)*	
	In favour of 2-4 days in between donations	s l
5-9 days vs > 10	days in between Males:	1, 6 vs 10 §
		1, 0 v3 10 3
donations (durin	Not statistically significant:	
	-17.8 ± 4 vs -19.1 ± 4 λ	
	MD: 1.3, 95%CI	
	[-2.75;5.35] (p=0.53)*	1, 17 vs 27 §
	Males:	· ·
	Higher than desired at baseline (130-159)	:
	Statistically significant:	
	-4.6±1.9 vs -0.4±1.8 λ	
	MD: -4.2, 95%CI	
	[-5.33;-3.07] (p<0.00001)*	
	In favour of 5-9 days in between donations	
	Males:	1, 79 vs 124 §
	Acceptable at baseline (<130):	
	Statistically significant:	
	5.4±1 vs 6.8±1.2 λ	
	MD: -1.4, 95%CI	

		[-1.71;-1.09] (p<0.00001)*		
		In favour of 5-9 days in between donations		
		Females:	1, 4 vs 8 §	
		High at baseline (≥160):	, , , , , , ,	
		Not statistically significant:		
		-20.8±4.8 vs -25.6±5 λ		
		MD: 4.8, 95%CI		
		[-1.04;10.64] (p=0.11)*		
		In favour of 5-9 days in between donations		
		Females:	1, 11 vs 12 §	
		Higher than desired at baseline (130-159):	1, 11 43 12 3	
		Statistically significant:		
		-10.5±2.5 vs -7.3±2.6 λ		
		MD: -3.2, 95%CI		
		[-5.02;-1.38] (p=0.0006)*		
		In favour of 5-9 days in between donations		
		Females:	1, 51 vs 104 §	
		Acceptable at baseline (<130):	1, 31 VS 104 V	
		Statistically significant:		
		$3.7\pm0.9 \text{ vs } 3\pm0.8 \lambda$		
		MD: 0.7, 95%CI		
		[0.41;0.99] (p<0.00001)*		
B I' t I I I I I I I I I I I I I I I I I	241 501 :11	In favour of ≥10 days in between donations	4 20 27 6	D D 2012
Predicted change in HDL cholesterol	2-4 days vs 5-9 days in between	Males:	1, 38 vs 27 §	Rosa-Bray, 2013
	donations (during 16 weeks)	Low at baseline (<40):		
		Statistically significant:		
		$2.3\pm0.6 \text{ vs } 4.7\pm0.8 \lambda$		
		MD: -2.4, 95%CI		
		[-2.76;-2.04] (p<0.00001)*		
		In favour of 5-9 days in between donations		
		Males:	1, 89 vs 63 §	
		Average at baseline (40-60):		
		Statistically significant:		
		-3.2±0.5 vs 0.3±0.6 λ		
		MD: -3.5, 95%CI		
		[-3.68;-3.32] (p<0.00001)*		
		In favour of 5-9 days in between donations		
		Males:	1, 17 vs 12 §	
		Optimal at baseline (>60):		

	T	
	Statistically significant:	
	-9.7±1.4 vs -5.4±1.5 λ	
	MD: -4.3, 95%CI	
	[-5.38;-3.22] (p<0.00001)*	
	In favour of 5-9 days in between donations	
	Females:	1, 25 vs 31 §
	Low at baseline (<50):	
	Statistically significant:	
	$\frac{1}{0\pm0.7}$ vs 2.7±0.6 λ	
	MD: -2.7, 95%CI	
	[-4.83;-0.57] (p=0.01)*a	
	In favour of 5-9 days in between donations	
	Females:	1, 19 vs 23 §
	Average at baseline (50-60):	1, 15 v3 £5 3
	Statistically significant:	
	-4.1 ± 0.7 vs -0.6 ± 0.7 λ	
	-4.1±0.7 vs -0.6±0.7 X MD: -3.5, 95%Cl	
	[-3.93;-3.07] (p<0.00001)*	
	In favour of 5-9 days in between donations	
	Females:	1, 10 vs 12 §
	Optimal at baseline (>60):	
	Statistically significant:	
	-10.8±1.5 vs -6.7±1.5 λ	
	MD: -4.1, 95%CI	
	[-5.36;-2.84] (p<0.00001)*	
	In favour of 5-9 days in between donations	
2-4 days vs ≥ 10 days in between	Males:	1, 38 vs 42 §
donations (during 16 weeks)	Low at baseline (<40):	
	Statistically significant:	
	2.3±0.6 vs 4.9±0.5 λ	
	MD: -2.6, 95%CI	
	[-2.84;-2.36] (p<0.00001)*	
	In favour of \geq 10 days in between donations	
	Males:	1, 89 vs 99 §
	Average at baseline (40-60):	., 55 .5 55 5
	Statistically significant:	
	$-3.2\pm0.5 \text{ vs } 0.3\pm0.5 \lambda$	
	MD: -3.5, 95%CI	
	[-3.64;-3.36] (p<0.00001)*	

	In favour of ≥10 days in between donations	
	Males:	1, 17 vs 19 §
	Optimal at baseline (>60):	1, 17 43 13 3
	Statistically significant:	
	-9.7±1.4 vs -3.5±1.6 λ	
	MD: -6.2, 95%CI	
	[-7.18;-5.22] (p<0.00001)*	
	In favour of \geq 10 days in between donations	
	Females:	1, 25 vs 64 §
	Low at baseline (<50):	1, 23 VS 04 9
	Statistically significant: $0\pm0.7 \text{ vs } 3.6\pm0.8 \lambda$	
	MD: -3.6, 95%CI	
	[-3.94;-3.26] (p<0.00001)*	
	In favour of ≥10 days in between donations	1 10 40 5
	Females:	1, 19 vs 48 §
	Average at baseline (50-60):	
	Statistically significant:	
	-4.1±0.7 vs 0.1±0.7 λ	
	MD: -4.2, 95%CI	
	[-4.57;-3.83] (p<0.00001)*	
	In favour of ≥10 days in between donations	
	Females:	1, 10 vs 24 §
	Optimal at baseline (>60):	
	Statistically significant:	
	-10.8±1.5 vs -4±1.5 λ	
	MD: -6.8, 95%CI	
	[-7.91;-5.69] (p<0.00001)*	
	In favour of \geq 10 days in between donations	
5-9 days vs ≥ 10 days in between	Males:	1, 27 vs 42 §
donations (during 16 weeks)	Low at baseline (<40):	
23.22.2. (22g . 2g)	Not statistically significant:	
	4.7±0.8 vs 4.9±0.5 λ	
	MD: -0.2, 95%CI	
	[-0.51;0.14] (p=0.25)*	
	Males:	1, 63 vs 99 §
	Average at baseline (40-60):	
	Average at baseline (40-60): Not statistically significant:	

MD: 0, 95%CI	
[-0.18;-0.18] (p=1)*	
Males:	1, 12 vs 19 §
Optimal at baseline (>60):	
Statistically significant:	
-5.4±1.5 vs -3.5±1.6 λ	
MD: -1.9, 95%CI	
[-3.01;-0.79] (p=0.0008)*	
In favour of ≥10 days in between donations	
Females:	1, 31 vs 64 §
Low at baseline (<50):	
Statistically significant:	
2.7±0.6 vs 3.6±0.8 λ	
MD: -0.9, 95%CI	
[-1.19;-0.61] (p<0.00001)*	
In favour of ≥10 days in between donations	
Females:	1, 23 vs 48 §
Average at baseline (50-60):	
Statistically significant:	
-0.6±0.7 vs 0.1±0.7 λ	
MD: -0.7, 95%CI	
[-1.05;-0.35] (p<0.0001)*	
In favour of ≥10 days in between donations	
Females:	1, 12 vs 24 §
Optimal at baseline (>60):	
Statistically significant:	
-6.7±1.5 vs -4±1.5 λ	
MD: -2.7, 95%CI	
[-3.74;-1.66] (p<0.00001)*	
In favour of ≥10 days in between donations	

Mean ± SD, MD: mean difference, SD: standard deviation

^{*} Calculations (MD, 95%CI) done by the reviewer(s) using Review Manager software

[§] Imprecision (limited sample size)

 $[\]lambda$ data extracted from graph using WebPlotDigitizer

^aNot statistically significant after applying the Holm-Bonferroni method. Given the multitude of pairwise comparisons that we performed using the data of Rosa-Bray (2013), the Holm-Bonferroni method was used to counteract the problem of multiple testing. Given that most p-values were very small, significance was unaffected by multiple testing corrections in all but two pairwise comparisons. The unadjusted p-values are shown.